Protagenic Therapeutics, Inc. Warrant
Compare this stock
PTIXW Stock Report Card
$
21%
Performance
Score:
10/100
PTIXW returned -30.00% in the last 12 months. Based on SPY's performance of -13.78%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
10/100
Out of the last 20 quarters, PTIXW has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
67/100
PTIXW has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.
Protagenic Therapeutics, Inc. Warrant Summary
Nasdaq / PTIXW
Healthcare
Biotechnology
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
PTIXW scored poorly on our reportcard. Here are some similar companies and how they performed.
